Moolec Science SA key statistics and ratios

In fiscal 2025, Moolec Science SA had an operating margin of -31.2% and a current ratio of 0.13. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Moolec Science SA: financial ratios, annual
Fiscal year	2023Jun 2023	2024Jun 2024	2025Jun 2025
Gross margin	44.1%	40.1%	39.0%
Operating margin	23.3%	4.1%	−31.2%
Net margin	9.6%	−7.0%	−33.4%
Free-cash-flow margin	−12.5%	6.4%	−0.6%
Return on equity	15.6%	−25.2%	—
Return on assets	168.1%	−6.7%	−19.3%
Asset turnover	17.50	0.96	0.58
Current ratio	0.42	1.03	0.13
Debt to equity	0.0%	>999%	—
Effective tax rate	−4.6%	—	—
R&D as % of revenue	3.8%	3.7%	4.5%
Capital spending as % of revenue	2.7%	2.1%	1.7%
Free cash flow ÷ net income	−130.2%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

0 of 4 checks passed · June 30, 2025

What it owns · $205m

Short-term assets $31mLonger-term assets $174m

What it owes, and who funded it · $288m

Short-term liabilities $236mLonger-term liabilities $52mShareholders' equity $-66m

Short-term assets cover short-term liabilities $31m of assets due within a year against $236m of liabilities due within a year.
Short-term assets cover long-term liabilities $31m short-term assets against $52m of longer-dated liabilities.
More cash than debt $767,919 of cash against $456m of debt.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt $4m of operating cash flow against $456m of debt.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Moolec Science SA's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IOVA vs MLEC ARVN vs MLEC ADPT vs MLEC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Moolec Science SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Moolec Science SA.